Summary of the American Heart Association’s Scientific Statement on Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents
- 1 May 2007
- journal article
- editorial
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 27 (5) , 982-985
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Drug Therapy of High-Risk Lipid Abnormalities in Children and AdolescentsCirculation, 2007
- Cardiovascular Risk Reduction in High-Risk Pediatric PatientsCirculation, 2006
- Efficacy and Safety of Lovastatin Therapy in Adolescent Girls With Heterozygous Familial HypercholesterolemiaPediatrics, 2005
- Efficacy and Safety of Statin Therapy in Children With Familial HypercholesterolemiaCirculation, 2002
- A Randomized Crossover Trial of Combination Pharmacologic Therapy in Children with Familial HyperlipidemiaPediatric Research, 2002
- Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: A randomized, crossover trialThe Journal of Pediatrics, 1997
- Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemiaThe Journal of Pediatrics, 1996
- Short-Term Efficacy and Safety of Pravastatin in 72 Children with Familial HypercholesterolemiaPediatric Research, 1996
- Low dose colestipol in adolescents with familial hypercholesterolaemia.Archives of Disease in Childhood, 1996
- Double blind trial of bezafibrate in familial hypercholesterolaemia.Archives of Disease in Childhood, 1985